Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy
Open Access
- 22 June 2020
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-13
Abstract
GDF-15 is a biomarker for mitochondrial diseases. We investigated the application of GDF-15 as biomarker of disease severity and response to deoxynucleoside treatment in patients with thymidine kinase 2 (TK2) deficiency and compared it to FGF-21. GDF-15 and FGF-21 were measured in serum from 24 patients with TK2 deficiency treated 1–49 months with oral deoxynucleosides. Patients were grouped according to age at treatment and biomarkers were analyzed at baseline and various time points after treatment initiation. GDF-15 was elevated on average 30-fold in children and 6-fold in adults before the start of treatment. There was a significant correlation between basal GDF-15 and severity based on pretreatment distance walked (6MWT) and weight (BMI). During treatment, GDF-15 significantly declined, and the decrease was accompanied by relevant clinical improvements. The decline was greater in the paediatric group, which included the most severe patients and showed the greatest clinical benefit, than in the adult patients. The decline of FGF-21 was less prominent and consistent. GDF-15 is a potential biomarker of severity and of therapeutic response for patients with TK2 deficiency. In addition, we show evidence of clinical benefit of deoxynucleoside treatment, especially when treatment is initiated at an early age.Keywords
This publication has 25 references indexed in Scilit:
- A comparison of current serum biomarkers as diagnostic indicators of mitochondrial diseasesNeurology, 2016
- GDF-15 Is Elevated in Children with Mitochondrial Diseases and Is Induced by Mitochondrial DysfunctionPLOS ONE, 2016
- Growth differentiation factor 15 as a useful biomarker for mitochondrial disordersAnnals of Neurology, 2015
- GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational ProspectiveJournal of Diabetes Research, 2015
- Fibroblast growth factor 21 protects the heart from oxidative stressCardiovascular Research, 2014
- Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathiesBMC Genomics, 2014
- Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndromeHuman Molecular Genetics, 2013
- The multiple facets of the TGF-β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1Cytokine & Growth Factor Reviews, 2013
- FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic studyThe Lancet Neurology, 2011
- The Transforming Growth Factor-β Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion InjuryCirculation Research, 2006